MYCN and Mobius syndrome: The high-risk (50–75% survival) cohort consists of all MYCN-amplified SHH-activated MBs (regardless of the metastatic status): TP53 wild-type, non-infant metastatic SHH-activated and metastatic Group 4 MBs [11].